Skip to content
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Aron – supplementaries
Contact Us
Menu
Home
About Us
Contributors
Publications
Aron 1 – Renal Cell Carcinoma
Aron 2 – Urothelial carcinoma
Aron 3 – Prostate Cancer
Aron – supplementaries
Contact Us
Publications
All our publications
Peripheral neuropathy and headache in cancer patients treated with immunotherapy andimmuno-oncology combinations: the MOUSEION-02 study
Alessandro Rizzo
et al. Expert Opin Drug Metab Toxicol
2021
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients:The MOUSEION-01 study
Matteo Santoni
et al. Crit Rev Oncol Hematol
2022
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Santoni M
. et al, Eur Urol Oncol
2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Massari F, et al.
Cancer Immunol Immunother.
2024
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Santoni M, et al.
Target Oncol.
2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, et al.
Eur Urol Oncol.
2024
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
